Heparin Sodium Injection by Hipre receives EMA approval for addition of new manufacturer.

Haiprui announcement, the company recently received approval notification from the European Medicines Agency for the addition of a new manufacturer of enoxaparin sodium injection. The approved drug is enoxaparin sodium injection, marketed as Inhixa, in the form of injections with specifications including 20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml, 100mg/1ml, 120mg/0.8ml, 150mg/1ml. The new manufacturer is Haiprui Pharmaceuticals Group Co., Ltd., with a production site located at 1 Rongtian Road, Kengzi Street, Pingshan District, Shenzhen, China. The approval number is EMA/VR/26.25. This approval will provide the company with sufficient production capacity to further advance its internationalization strategy for formulations and effectively enhance the company's market competitiveness.